Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TheraPEG patent highlights benefits of PEGylation technology

This article was originally published in Scrip

Executive Summary

PolyTherics’ European patent for its TheraPEG PEGylation technology (www.scripnews.com, 22 June 2009) is indeed a significant milestone for the company. With allowance of the US TheraPEG patent expected “very soon”, all products incorporating the TheraPEG technology will be protected throughout their development and once they reach the market. This will not only secure commercial freedom for those products but, going forward, it will also generate licensing and royalty revenues for PolyTherics.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC002832

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel